Drug Targets – Webinars and Online Events

With unrivaled flexibility and high sensitivity, the WAVE brings label-free quantification to a whole new world of applications, revolutionizing the study of biomolecular interactions.

Alzheimer’s disease is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer’s disease.

In this webinar, we host two speakers who will present diverse case studies that will illustrate how multiomics is being used to deepen our understanding of human biology.

Learn how scientists in the drug discovery field search for the most promising lead compounds. Dr. Claire Hatty from NanoTemper will highlight case studies demonstrating the value of biophysical tools in drug discovery workflows.

Understanding the tissue-specific genetic architecture of protein levels is instrumental to understand the biology of health and disease.

Although the primary focus of the pharmaceutical industry has been identifying the mechanisms of drug elimination and potential drug liability, there is now an increasing focus on the kidney as a therapeutic target.

This webinar will introduce the native MS and lipid nanodisc technique as well as demonstrate how this approach can be used to directly measure the oligomeric state of protein and peptide complexes within intact model lipid bilayers. Ongoing studies on the M2 and E protein will be discussed.